Strong R&D commitment
Merck Serono has its own integrated research and development facilities as well as a network of alliances with other biotech companies and academic groups. Each year we commit 25% of total revenues to discover and develop new therapies.
New approaches in cancer therapy
We are working on the development of therapies that specifically target cancer cells without damaging healthy cells. Merck Serono’s focus on the development of targeted cancer therapies is on three therapeutic platforms: targeting the tumor cell, the tumor environment and the immune system.
Pioneering technology for patients
Merck Serono also works hard to make our medicines easier for patients to take.
Business Development at Merck Serono plays a key role in delivering new products to supplement the internal R&D pipeline.
Area of interest
Product opportunities in therapeutic areas aligned with the existing business units are of interest;
Neurology, Autoimmune and Inflammation, Reproductive Health, Growth Hormone, Cardiology, Diabetes & Oncology
Key interest drivers include products or near to market products used in a specialist care setting and with sales (or expected sales) in the UK and/or Europe (or subsets of European countries).
Exceptions to this will be considered on a case by case basis e.g. products or near to market products in other disease areas.
Opportunity Analysis Process
Merck Serono has a dedicated Business Development team covering the UK and Europe. Please direct queries to the contact information supplied.
After an initial discussion, a detailed review of the product offering will be undertaken. Information required includes sales data (including competition where appropriate), forecasts, patent position, a list of countries which are offered and outline deal type.
Contacts
Email:
bd.uk@merckserono.net
Phone: 020 8818 7275